ReviewKlinische Monatsblatter fur Augenheilkunde2025
Understanding Glaucoma: Why it Remains a Leading Cause of Blindness Worldwide.
Review in Klinische Monatsblatter fur Augenheilkunde, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The risk association between systemic lupus erythematosus and glaucoma: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Future visual field prediction in glaucoma: an application of first-order autoregressive approach.International ophthalmology · 2026Article
- Extracellular vesicles as therapeutic agents for retinal ganglion cell degeneration: current challenges and future prospects.International ophthalmology · 2026Review
- Wirelessly Interrogated, Implantable Capacitive MEMS Sensors for Continuous Intraocular Pressure Monitoring.Sensors (Basel, Switzerland) · 2026Article
- Sex Differences in Intraocular Pressure and Retinal Vessel Responses After Sustained Isometric Knee Extension in Young Adults: A Quasi-Experimental Study.Journal of clinical medicine · 2026Article
- Network Analysis of Convergent and Specific Molecular Pathways of Nutraceuticals with Antioxidant and Neuroprotective Potential in Glaucoma.Antioxidants (Basel, Switzerland) · 2026Article
- Macrophage Migration Inhibitory Factor (MIF)-CD74 Signaling Pathway Mediates Trabecular Meshwork Dysfunction in Glaucoma.bioRxiv : the preprint server for biology · 2026Article
- Role of Growth Hormone (GH) and Other Somatotropic Axis Elements in Retinal Neuroprotection.Current issues in molecular biology · 2026Review
- Altered serum biomarkers of oxidative stress and antioxidant capacity in primary open-angle glaucoma.Scientific reports · 2026Article
- Possible Effects of Topical Rho-Kinase Inhibitor on Schlemm's Canal Morphology Parameters.Biomedicines · 2026Article
- Robust benchmarking of DeepLabv3 hybrid models for multiclass fundus screening and referable-disease triage on the FIVES dataset.Frontiers in medicine · 2026Article
- Association of the TGF-beta1 polymorphism with primary open-angle glaucoma: a case-control study.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Article
- Molecular and Histological Characterization of a Novel Hydrogel-Based Strategy for Inducing Experimental Glaucoma in Mice.International journal of molecular sciences · 2025Article
- Multifactorial analysis of dry eye syndrome: insights from Schirmer's test, VDT exposure, and tear film stability.International ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma is one of the leading causes of irreversible blindness worldwide and is often referred to as the "silent thief of sight", because it often progresses without noticeable symptoms until significant vision loss occurs. With an estimated 76 million patients affected in 2020 and a forecast of over 111 million by 2040, the global situation requires urgent attention. Vision loss caused by glaucoma is irreversible but largely preventable, highlighting the importance of early detection and treatment. Diagnosis presents significant challenges, particularly due to the asymptomatic nature of the disease and age-related risk factors. Inequalities in care and access to appropriate treatments are other barriers leading to delayed diagnoses. Early diagnosis and interventions are critical to slow disease progression, protect remaining vision and improve the quality of life of those affected. These measures are particularly important to minimise the psychological impact and impairment in daily activities. The use of innovative technologies and targeted interventions could help improve the early detection and treatment of glaucoma and thus reduce the risk of irreversible vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.